Rockwell Medical Inc  

(Public, NASDAQ:RMTI)   Watch this stock  
Find more results for RMTI
8.24
0.00 (0.00%)
Dec 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 8.10 - 14.80
Open     -
Vol / Avg. 0.00/774,543.00
Mkt cap 391.76M
P/E     -
Div/yield     -
EPS -0.58
Shares 47.52M
Beta 1.29
Inst. own 29%
Feb 24, 2015
Q4 2014 Rockwell Medical Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 10, 2014
Q3 2014 Rockwell Medical Inc Earnings Call - Webcast
Nov 10, 2014
Q3 2014 Rockwell Medical Inc Earnings Release
Oct 3, 2014
Rockwell Medical Inc Enters Into Exclusive Long-Term Agreement With Baxter Healthcare to Commercialize Rockwell's Hemodialysis Concentrates
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -28.87% -93.13%
Operating margin -22.78% -89.84%
EBITD margin - -87.92%
Return on average assets -63.97% -182.75%
Return on average equity - -
Employees 286 -
CDP Score - -

Address

30142 S Wixom Rd
WIXOM, MI 48393-3440
United States - Map
+1-248-9609009 (Phone)
+1-248-9609119 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patient�s bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.

Officers and directors

Robert L. Chioini Chairman of the Board, President, Chief Executive Officer
Age: 49
Bio & Compensation  - Reuters
Thomas E. Klema CPA Chief Financial Officer, Vice President, Treasurer, Secretary
Age: 60
Bio & Compensation  - Reuters
Ajay Gupta M.D. Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters
Raymond D. Pratt M.D. Chief Medical Officer
Age: 63
Bio & Compensation  - Reuters
Patrick J. Bagley Independent Director
Age: 66
Bio & Compensation  - Reuters
Ronald D. Boyd Independent Director
Age: 51
Bio & Compensation  - Reuters
Kenneth L. Holt Independent Director
Age: 61
Bio & Compensation  - Reuters